SixLog Pharma \u2014 Operational, Regulatory, and Coverage Advisory for Sterile Compounding<\/title>\n<style>\n :root{\n --ink:#0f1c24; \/* deep institutional ink *\/\n --slate:#33454f; \/* slate for secondary *\/\n --paper:#fbfaf7; \/* cool bone white *\/\n --paper-2:#f1efe9;\n --steel:#2f5d6b; \/* clinical steel-teal accent *\/\n --steel-bright:#3f7d8f;\n --brass:#9a7b3f; \/* brass hairline accent, used sparingly *\/\n --line:#dcd8ce;\n --line-dark:#20323b;\n --muted:#6a6b66;\n --white:#ffffff;\n }\n *{margin:0;padding:0;box-sizing:border-box}\n html{scroll-behavior:smooth}\n body{\n font-family:'IBM Plex Sans',-apple-system,BlinkMacSystemFont,sans-serif;\n color:var(--ink);background:var(--paper);line-height:1.6;font-size:16.5px;\n -webkit-font-smoothing:antialiased;\n }\n h1,h2,h3,.serif{font-family:'Newsreader',Georgia,serif;font-weight:400}\n .mono{font-family:'IBM Plex Mono',monospace}\n .wrap{max-width:1120px;margin:0 auto;padding:0 40px}\n .narrow{max-width:720px}\n\n \/* eyebrow \/ labels use mono for a clinical, documentary feel *\/\n .eyebrow{\n font-family:'IBM Plex Mono',monospace;font-size:11.5px;letter-spacing:2.5px;\n text-transform:uppercase;color:var(--steel);font-weight:500\n }\n\n \/* ---- top bar ---- *\/\n .topbar{border-bottom:1px solid var(--line);background:var(--paper);position:sticky;top:0;z-index:50}\n .topbar .wrap{display:flex;justify-content:space-between;align-items:center;height:76px}\n .brand{display:flex;align-items:baseline;gap:2px;text-decoration:none;color:var(--ink)}\n .brand .mark{font-family:'Newsreader',serif;font-size:22px;letter-spacing:.2px}\n .brand .mark b{font-weight:500}\n .brand .logo-img{height:100px;width:auto;display:block}\n .topbar nav a{\n font-family:'IBM Plex Mono',monospace;color:var(--slate);text-decoration:none;\n font-size:12.5px;letter-spacing:1px;text-transform:uppercase;margin-left:34px\n }\n .topbar nav a:hover{color:var(--steel)}\n @media(max-width:680px){.topbar nav{display:none}}\n\n \/* ---- hero ---- *\/\n .hero{padding:104px 0 20px;position:relative}\n .hero .eyebrow{margin-bottom:30px}\n .hero h1{\n font-size:56px;line-height:1.1;letter-spacing:-.4px;color:var(--ink);max-width:16ch;font-weight:400\n }\n .hero h1 em{font-style:italic;color:var(--steel)}\n .hero .lede{\n font-size:19px;color:var(--slate);margin-top:32px;max-width:60ch;line-height:1.62\n }\n @media(max-width:720px){.hero h1{font-size:39px}.hero{padding:70px 0 10px}}\n\n \/* ---- the spine: prevent \/ survive ---- *\/\n .spine{padding:80px 0 0}\n .spine .grid{display:grid;grid-template-columns:1fr 1fr;border-top:1px solid var(--ink)}\n .spine .cell{padding:34px 40px 40px;border-right:1px solid var(--line)}\n .spine .cell:last-child{border-right:none;background:var(--ink);color:var(--paper);margin:-1px -40px -1px 0;padding:34px 40px 40px 40px}\n .spine .cell .idx{font-family:'IBM Plex Mono',monospace;font-size:12px;letter-spacing:1px;color:var(--brass);margin-bottom:18px}\n .spine .cell:last-child .idx{color:var(--steel-bright)}\n .spine .cell h3{font-size:27px;margin-bottom:14px;line-height:1.2}\n .spine .cell:last-child h3{color:var(--white)}\n .spine .cell p{font-size:15.5px;color:var(--slate);line-height:1.6}\n .spine .cell:last-child p{color:rgba(251,250,247,.82)}\n .spine .verdict{\n text-align:center;padding:30px 0 0;font-family:'Newsreader',serif;font-style:italic;\n font-size:19px;color:var(--steel)\n }\n @media(max-width:720px){\n .spine .grid{grid-template-columns:1fr}\n .spine .cell{border-right:none;border-bottom:1px solid var(--line)}\n .spine .cell:last-child{margin:0}\n }\n\n \/* ---- section base ---- *\/\n section{padding:92px 0}\n .sec-head{max-width:64ch;margin-bottom:8px}\n .sec-head .eyebrow{display:block;margin-bottom:20px}\n .sec-h{font-size:35px;line-height:1.22;letter-spacing:-.3px;color:var(--ink);max-width:20ch}\n .sec-p{font-size:17px;color:var(--slate);max-width:62ch;line-height:1.62;margin-top:20px}\n\n \/* ---- services: institutional numbered ledger ---- *\/\n .svc{border-top:1px solid var(--line)}\n .svc .rows{margin-top:56px;border-top:1px solid var(--ink)}\n .svc .row{\n display:grid;grid-template-columns:80px 1fr 2fr;gap:32px;align-items:start;\n padding:30px 0;border-bottom:1px solid var(--line)\n }\n .svc .row .num{font-family:'IBM Plex Mono',monospace;font-size:13px;color:var(--steel);padding-top:5px}\n .svc .row h3{font-size:22px;line-height:1.25;color:var(--ink)}\n .svc .row p{font-size:15.5px;color:var(--slate);line-height:1.6}\n @media(max-width:760px){\n .svc .row{grid-template-columns:44px 1fr;gap:14px 18px}\n .svc .row p{grid-column:1\/-1;margin-top:2px}\n }\n\n \/* ---- who ---- *\/\n .who{background:var(--paper-2);border-top:1px solid var(--line);border-bottom:1px solid var(--line)}\n .who .list{margin-top:44px;display:grid;grid-template-columns:1fr 1fr;gap:0 60px}\n .who .list .li{\n display:flex;gap:16px;padding:18px 0;border-bottom:1px solid var(--line);align-items:baseline\n }\n .who .list .li .m{font-family:'IBM Plex Mono',monospace;font-size:12px;color:var(--steel);flex-shrink:0;width:34px}\n .who .list .li .t{font-size:16px;color:var(--slate)}\n .who .list .li .t b{color:var(--ink);font-weight:600}\n @media(max-width:640px){.who .list{grid-template-columns:1fr;gap:0}}\n\n \/* ---- bio ---- *\/\n .bio .grid{display:grid;grid-template-columns:1.5fr 1fr;gap:64px;align-items:start;margin-top:20px}\n .bio h2{font-size:31px;margin-bottom:6px;line-height:1.2}\n .bio .role{font-family:'IBM Plex Mono',monospace;font-size:12px;letter-spacing:1.5px;text-transform:uppercase;color:var(--steel);margin-bottom:26px}\n .bio p{font-size:16.5px;color:var(--slate);margin-bottom:16px;line-height:1.64}\n .bio p b{color:var(--ink);font-weight:600}\n .bio .creds{font-family:'IBM Plex Mono',monospace;font-size:12.5px;color:var(--muted);margin-top:24px;line-height:1.8;letter-spacing:.3px}\n .bio .card{\n background:var(--ink);border-radius:3px;padding:32px 30px;color:var(--paper);position:sticky;top:100px\n }\n .bio .card .k{font-family:'IBM Plex Mono',monospace;font-size:11px;letter-spacing:2px;text-transform:uppercase;color:var(--steel-bright);margin-bottom:16px}\n .bio .card .line{font-family:'Newsreader',serif;font-size:19px;line-height:1.4;color:var(--white);margin-bottom:18px}\n .bio .card .sub{font-size:14px;color:rgba(251,250,247,.7);line-height:1.6}\n @media(max-width:760px){.bio .grid{grid-template-columns:1fr;gap:36px}.bio .card{position:static}}\n\n \/* ---- brokerage band ---- *\/\n .band{background:var(--ink);color:var(--paper)}\n .band .wrap{padding:64px 40px;display:grid;grid-template-columns:auto 1fr;gap:48px;align-items:center}\n .band .k{font-family:'IBM Plex Mono',monospace;font-size:11px;letter-spacing:2px;text-transform:uppercase;color:var(--steel-bright);white-space:nowrap}\n .band p{font-family:'Newsreader',serif;font-size:21px;line-height:1.5;color:rgba(251,250,247,.92)}\n .band p b{color:var(--white);font-weight:500}\n @media(max-width:680px){.band .wrap{grid-template-columns:1fr;gap:18px}}\n\n \/* ---- contact ---- *\/\n .contact{padding:100px 0;text-align:center}\n .contact .eyebrow{margin-bottom:22px}\n .contact h2{font-size:36px;line-height:1.22;max-width:20ch;margin:0 auto 22px;color:var(--ink);font-weight:400}\n .contact .sec-p{margin:0 auto 40px;text-align:center}\n .contact .btn{\n display:inline-block;background:var(--steel);color:var(--white);text-decoration:none;\n font-family:'IBM Plex Sans',sans-serif;font-size:15px;font-weight:600;letter-spacing:.3px;\n padding:16px 40px;border-radius:3px;transition:background .2s\n }\n .contact .btn:hover{background:var(--ink)}\n .contact .direct{margin-top:34px;font-family:'IBM Plex Mono',monospace;font-size:13.5px;color:var(--muted);letter-spacing:.5px}\n .contact .direct a{color:var(--ink);text-decoration:none;border-bottom:1px solid var(--brass);padding-bottom:2px}\n .contact .direct a:hover{color:var(--steel)}\n .contact .direct .sep{margin:0 14px;color:var(--line)}\n\n \/* ---- footer ---- *\/\n footer{border-top:1px solid var(--line);background:var(--paper)}\n footer .wrap{padding:40px 40px;display:flex;justify-content:space-between;align-items:center;flex-wrap:wrap;gap:16px}\n footer .brand .mark{font-size:18px}\n footer .tag{font-family:'Newsreader',serif;font-style:italic;font-size:15px;color:var(--steel)}\n footer .fine{width:100%;font-size:12px;color:#a29f96;line-height:1.65;border-top:1px solid var(--line);padding-top:22px;margin-top:8px;font-family:'IBM Plex Sans',sans-serif}\n<\/style>\n<\/head>\n<body>\n\n<div class=\"topbar\">\n <div class=\"wrap\">\n <a href=\"#top\" class=\"brand\">\n <img decoding=\"async\" src=\"https:\/\/sixlogpharma.com\/wp-content\/uploads\/2025\/02\/teal.png\" alt=\"SixLog Pharma\" class=\"logo-img\"> \n \n <\/a>\n <nav>\n <a href=\"#work\">Services<\/a>\n <a href=\"#who\">Who we help<\/a>\n <a href=\"#about\">About<\/a>\n <a href=\"#contact\">Contact<\/a>\n <\/nav>\n <\/div>\n<\/div>\n\n<a id=\"top\"><\/a>\n<header class=\"hero\">\n <div class=\"wrap\">\n <div class=\"eyebrow\">Operational \u00b7 Regulatory \u00b7 Coverage Advisory<\/div>\n <h1>Sterile compounding fails in two places. We work on <em>both.<\/em><\/h1>\n <p class=\"lede\">\n SixLog Pharma helps sterile compounding operations see their full risk picture: how the operation\n runs, where it is exposed, and whether the coverage behind it would respond when something slips\n through. Led by a former 503B owner-operator, we read the operation and the policy from the inside.\n <\/p>\n <\/div>\n<\/header>\n\n<div class=\"spine\">\n <div class=\"wrap\">\n <div class=\"grid\">\n <div class=\"cell\">\n <div class=\"idx\">01 \/ PREVENTION<\/div>\n <h3>Keeping the event from happening<\/h3>\n <p>\n The quality system, environmental monitoring, aseptic technique, CAPA discipline. The work\n that stops the excursion, the failed media fill, the contamination event. Most good operators\n have built this half with real rigor.\n <\/p>\n <\/div>\n <div class=\"cell\">\n <div class=\"idx\">02 \/ SURVIVAL<\/div>\n <h3>Surviving the one that gets through<\/h3>\n <p>\n A recall, a regulatory hold, an officer named personally. Whether the coverage behind the\n business actually responds, or was quietly written for a smaller, simpler version of the\n company. This is the half almost no one checks.\n <\/p>\n <\/div>\n <\/div>\n <div class=\"verdict\">Operations prevent the event. Coverage decides whether the business survives it.<\/div>\n <\/div>\n<\/div>\n\n<section id=\"work\" class=\"svc\">\n <div class=\"wrap\">\n <div class=\"sec-head\">\n <span class=\"eyebrow\">Services<\/span>\n <h2 class=\"sec-h\">Operations and coverage, read from the operator's side.<\/h2>\n <p class=\"sec-p\">\n Most advisors see one half. A quality consultant reads the operation. A broker reads the policy.\n We read both, because they are the same risk, and we read them the way someone does who has run\n the facility and made the call.\n <\/p>\n <\/div>\n <div class=\"rows\">\n <div class=\"row\">\n <div class=\"num\">01<\/div>\n <h3>Operational risk review<\/h3>\n <p>An operator's read of the facility, quality systems, and practices. Where the operation is vulnerable, what an inspection would surface, and what it means for the business, not just the quality file.<\/p>\n <\/div>\n <div class=\"row\">\n <div class=\"num\">02<\/div>\n <h3>Coverage review<\/h3>\n <p>A line-by-line read of the insurance program against what the operation actually does: recall trigger, business interruption from a shutdown, D&O exposure, limits sized to current volume, and the exclusions buried in the endorsements.<\/p>\n <\/div>\n <div class=\"row\">\n <div class=\"num\">03<\/div>\n <h3>Regulatory remediation<\/h3>\n <p>Support through 483 responses, warning letters, and remediation. Building a response that addresses the system, not just the observations, from someone who has been on the receiving end of an inspection.<\/p>\n <\/div>\n <div class=\"row\">\n <div class=\"num\">04<\/div>\n <h3>Transaction diligence<\/h3>\n <p>For buyers, investors, and operators in a deal: an independent read on where a target's operation, compliance, and coverage actually stand, before the exposure becomes yours.<\/p>\n <\/div>\n <\/div>\n <\/div>\n<\/section>\n\n<section id=\"who\" class=\"who\">\n <div class=\"wrap\">\n <div class=\"sec-head\">\n <span class=\"eyebrow\">Who we help<\/span>\n <h2 class=\"sec-h\">The people who own the exposure.<\/h2>\n <\/div>\n <div class=\"list\">\n <div class=\"li\"><span class=\"m\">A<\/span><span class=\"t\"><b>503B outsourcing facilities<\/b> and sterile compounding operations<\/span><\/div>\n <div class=\"li\"><span class=\"m\">B<\/span><span class=\"t\"><b>503A pharmacies<\/b> scaling into new lines or volume<\/span><\/div>\n <div class=\"li\"><span class=\"m\">C<\/span><span class=\"t\"><b>Owners<\/b> preparing for growth, a raise, or a sale<\/span><\/div>\n <div class=\"li\"><span class=\"m\">D<\/span><span class=\"t\"><b>Investors and PE groups<\/b> underwriting a pharmacy acquisition<\/span><\/div>\n <div class=\"li\"><span class=\"m\">E<\/span><span class=\"t\"><b>Consultants<\/b> who advise operators and need the coverage piece<\/span><\/div>\n <div class=\"li\"><span class=\"m\">F<\/span><span class=\"t\"><b>Boards and officers<\/b> exposed personally to regulatory action<\/span><\/div>\n <\/div>\n <\/div>\n<\/section>\n\n<section id=\"about\" class=\"bio\">\n <div class=\"wrap\">\n <div class=\"sec-head\"><span class=\"eyebrow\">About<\/span><\/div>\n <div class=\"grid\">\n <div>\n <h2>Brian Williamson, PharmD<\/h2>\n <div class=\"role\">Founder, SixLog Pharma<\/div>\n <p>\n We built, ran, and sold a nationally recognized sterile compounding pharmacy and FDA-registered\n 503B outsourcing facility. We have lived the environmental excursion, the recall decision, the\n inspection, the choice between stopping a line and pushing through. <b>We know what these\n operations are exposed to, because we ran one.<\/b>\n <\/p>\n <p>\n After building and selling in this industry, we turned to the risks operators live with but rarely have\n time to step back and see whole: the operational exposures, the regulatory ones, and the\n coverage that is supposed to catch what gets through. <b>Seeing that full picture is the work\n now.<\/b>\n <\/p>\n <p>\n We read coverage the way an operator reads a facility: against what the business actually does,\n looking for what others miss. When placement is needed, we work with a specialty life science\n insurance brokerage with real depth in reviewing and structuring policies for high-hazard risk.\n <\/p>\n <p>\n This is not theory from the sidelines. We are actively engaged today, advising sterile\n compounding operators, supporting regulatory remediation, and conducting operational and\n coverage due diligence on live transactions. <b>We do this work now, in the field, not from a\n past life.<\/b>\n <\/p>\n\n <\/div>\n <div class=\"card\">\n <div class=\"k\">Former 503B Owner-Operator<\/div>\n <div class=\"line\">Built it. Ran it. Sold it.<\/div>\n <div class=\"sub\">Now we read the operation and the coverage behind operations like the ones we ran, from the inside.<\/div>\n <\/div>\n <\/div>\n <\/div>\n<\/section>\n\n<div class=\"band\">\n <div class=\"wrap\">\n <div class=\"k\">Placement Partner<\/div>\n <p>\n When coverage needs to be placed or restructured, we work alongside a <b>specialty life science\n insurance brokerage<\/b> with real expertise in reviewing and structuring policies for high-hazard,\n highly regulated operations.\n <\/p>\n <\/div>\n<\/div>\n\n<section id=\"contact\" class=\"contact\">\n <div class=\"wrap narrow\">\n <span class=\"eyebrow\">Start here<\/span>\n <h2>Would your coverage respond to the recall you're most likely to make?<\/h2>\n <p class=\"sec-p\">\n Most operators have never checked. A short conversation is usually enough to know whether it is\n worth a closer look. No pitch, no obligation.\n <\/p>\n <a href=\"mailto:brian@sixlogpharma.com?subject=SixLog%20risk%20and%20coverage%20review\" class=\"btn\">Request a review<\/a>\n <div class=\"direct\">\n <a href=\"mailto:brian@sixlogpharma.com?subject=SixLog%20risk%20and%20coverage%20review\">brian@sixlogpharma.com<\/a>\n <span class=\"sep\">\/<\/span>316.304.5501\n <\/div>\n <\/div>\n<\/section>\n\n<footer>\n <div class=\"wrap\">\n <a href=\"#top\" class=\"brand\"><span class=\"mark\"><b>SixLog<\/b> Pharma<\/span><\/a>\n <div class=\"tag\">Find the gaps before the gaps find you.<\/div>\n <div class=\"fine\">\n SixLog Pharma is a risk advisory practice led by a former 503A and 503B owner-operator. Insurance\n placement is handled in partnership with a licensed specialty insurance brokerage. Content on this\n site is educational and general in nature and is not insurance, legal, or financial advice. Actual\n coverage depends entirely on the specific terms, forms, and endorsements of a given program.\n <\/div>\n <\/div>\n<\/footer>\n\n<\/body>\n<\/html>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>SixLog Pharma \u2014 Operational, Regulatory, and Coverage Advisory for Sterile Compounding Services Who we help About Contact Operational \u00b7 Regulatory \u00b7 Coverage Advisory Sterile compounding fails in two places. We work on both. SixLog Pharma helps sterile compounding operations see their full risk picture: how the operation runs, where it is exposed, and whether the …<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_canvas","meta":{"_genesis_block_theme_hide_title":false,"footnotes":""},"class_list":["post-41","page","type-page","status-publish","hentry","post","without-featured-image"],"_links":{"self":[{"href":"https:\/\/sixlogpharma.com\/index.php?rest_route=\/wp\/v2\/pages\/41","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sixlogpharma.com\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/sixlogpharma.com\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/sixlogpharma.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/sixlogpharma.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41"}],"version-history":[{"count":11,"href":"https:\/\/sixlogpharma.com\/index.php?rest_route=\/wp\/v2\/pages\/41\/revisions"}],"predecessor-version":[{"id":55,"href":"https:\/\/sixlogpharma.com\/index.php?rest_route=\/wp\/v2\/pages\/41\/revisions\/55"}],"wp:attachment":[{"href":"https:\/\/sixlogpharma.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

\n\t\t\t\t

\n\t\t\t\t\t\n\n\n\n\n\n\n\nSixLog Pharma \u2014 Operational, Regulatory, and Coverage Advisory for Sterile Compounding<\/title>\n<style>\n :root{\n --ink:#0f1c24; \/* deep institutional ink *\/\n --slate:#33454f; \/* slate for secondary *\/\n --paper:#fbfaf7; \/* cool bone white *\/\n --paper-2:#f1efe9;\n --steel:#2f5d6b; \/* clinical steel-teal accent *\/\n --steel-bright:#3f7d8f;\n --brass:#9a7b3f; \/* brass hairline accent, used sparingly *\/\n --line:#dcd8ce;\n --line-dark:#20323b;\n --muted:#6a6b66;\n --white:#ffffff;\n }\n *{margin:0;padding:0;box-sizing:border-box}\n html{scroll-behavior:smooth}\n body{\n font-family:'IBM Plex Sans',-apple-system,BlinkMacSystemFont,sans-serif;\n color:var(--ink);background:var(--paper);line-height:1.6;font-size:16.5px;\n -webkit-font-smoothing:antialiased;\n }\n h1,h2,h3,.serif{font-family:'Newsreader',Georgia,serif;font-weight:400}\n .mono{font-family:'IBM Plex Mono',monospace}\n .wrap{max-width:1120px;margin:0 auto;padding:0 40px}\n .narrow{max-width:720px}\n\n \/* eyebrow \/ labels use mono for a clinical, documentary feel *\/\n .eyebrow{\n font-family:'IBM Plex Mono',monospace;font-size:11.5px;letter-spacing:2.5px;\n text-transform:uppercase;color:var(--steel);font-weight:500\n }\n\n \/* ---- top bar ---- *\/\n .topbar{border-bottom:1px solid var(--line);background:var(--paper);position:sticky;top:0;z-index:50}\n .topbar .wrap{display:flex;justify-content:space-between;align-items:center;height:76px}\n .brand{display:flex;align-items:baseline;gap:2px;text-decoration:none;color:var(--ink)}\n .brand .mark{font-family:'Newsreader',serif;font-size:22px;letter-spacing:.2px}\n .brand .mark b{font-weight:500}\n .brand .logo-img{height:100px;width:auto;display:block}\n .topbar nav a{\n font-family:'IBM Plex Mono',monospace;color:var(--slate);text-decoration:none;\n font-size:12.5px;letter-spacing:1px;text-transform:uppercase;margin-left:34px\n }\n .topbar nav a:hover{color:var(--steel)}\n @media(max-width:680px){.topbar nav{display:none}}\n\n \/* ---- hero ---- *\/\n .hero{padding:104px 0 20px;position:relative}\n .hero .eyebrow{margin-bottom:30px}\n .hero h1{\n font-size:56px;line-height:1.1;letter-spacing:-.4px;color:var(--ink);max-width:16ch;font-weight:400\n }\n .hero h1 em{font-style:italic;color:var(--steel)}\n .hero .lede{\n font-size:19px;color:var(--slate);margin-top:32px;max-width:60ch;line-height:1.62\n }\n @media(max-width:720px){.hero h1{font-size:39px}.hero{padding:70px 0 10px}}\n\n \/* ---- the spine: prevent \/ survive ---- *\/\n .spine{padding:80px 0 0}\n .spine .grid{display:grid;grid-template-columns:1fr 1fr;border-top:1px solid var(--ink)}\n .spine .cell{padding:34px 40px 40px;border-right:1px solid var(--line)}\n .spine .cell:last-child{border-right:none;background:var(--ink);color:var(--paper);margin:-1px -40px -1px 0;padding:34px 40px 40px 40px}\n .spine .cell .idx{font-family:'IBM Plex Mono',monospace;font-size:12px;letter-spacing:1px;color:var(--brass);margin-bottom:18px}\n .spine .cell:last-child .idx{color:var(--steel-bright)}\n .spine .cell h3{font-size:27px;margin-bottom:14px;line-height:1.2}\n .spine .cell:last-child h3{color:var(--white)}\n .spine .cell p{font-size:15.5px;color:var(--slate);line-height:1.6}\n .spine .cell:last-child p{color:rgba(251,250,247,.82)}\n .spine .verdict{\n text-align:center;padding:30px 0 0;font-family:'Newsreader',serif;font-style:italic;\n font-size:19px;color:var(--steel)\n }\n @media(max-width:720px){\n .spine .grid{grid-template-columns:1fr}\n .spine .cell{border-right:none;border-bottom:1px solid var(--line)}\n .spine .cell:last-child{margin:0}\n }\n\n \/* ---- section base ---- *\/\n section{padding:92px 0}\n .sec-head{max-width:64ch;margin-bottom:8px}\n .sec-head .eyebrow{display:block;margin-bottom:20px}\n .sec-h{font-size:35px;line-height:1.22;letter-spacing:-.3px;color:var(--ink);max-width:20ch}\n .sec-p{font-size:17px;color:var(--slate);max-width:62ch;line-height:1.62;margin-top:20px}\n\n \/* ---- services: institutional numbered ledger ---- *\/\n .svc{border-top:1px solid var(--line)}\n .svc .rows{margin-top:56px;border-top:1px solid var(--ink)}\n .svc .row{\n display:grid;grid-template-columns:80px 1fr 2fr;gap:32px;align-items:start;\n padding:30px 0;border-bottom:1px solid var(--line)\n }\n .svc .row .num{font-family:'IBM Plex Mono',monospace;font-size:13px;color:var(--steel);padding-top:5px}\n .svc .row h3{font-size:22px;line-height:1.25;color:var(--ink)}\n .svc .row p{font-size:15.5px;color:var(--slate);line-height:1.6}\n @media(max-width:760px){\n .svc .row{grid-template-columns:44px 1fr;gap:14px 18px}\n .svc .row p{grid-column:1\/-1;margin-top:2px}\n }\n\n \/* ---- who ---- *\/\n .who{background:var(--paper-2);border-top:1px solid var(--line);border-bottom:1px solid var(--line)}\n .who .list{margin-top:44px;display:grid;grid-template-columns:1fr 1fr;gap:0 60px}\n .who .list .li{\n display:flex;gap:16px;padding:18px 0;border-bottom:1px solid var(--line);align-items:baseline\n }\n .who .list .li .m{font-family:'IBM Plex Mono',monospace;font-size:12px;color:var(--steel);flex-shrink:0;width:34px}\n .who .list .li .t{font-size:16px;color:var(--slate)}\n .who .list .li .t b{color:var(--ink);font-weight:600}\n @media(max-width:640px){.who .list{grid-template-columns:1fr;gap:0}}\n\n \/* ---- bio ---- *\/\n .bio .grid{display:grid;grid-template-columns:1.5fr 1fr;gap:64px;align-items:start;margin-top:20px}\n .bio h2{font-size:31px;margin-bottom:6px;line-height:1.2}\n .bio .role{font-family:'IBM Plex Mono',monospace;font-size:12px;letter-spacing:1.5px;text-transform:uppercase;color:var(--steel);margin-bottom:26px}\n .bio p{font-size:16.5px;color:var(--slate);margin-bottom:16px;line-height:1.64}\n .bio p b{color:var(--ink);font-weight:600}\n .bio .creds{font-family:'IBM Plex Mono',monospace;font-size:12.5px;color:var(--muted);margin-top:24px;line-height:1.8;letter-spacing:.3px}\n .bio .card{\n background:var(--ink);border-radius:3px;padding:32px 30px;color:var(--paper);position:sticky;top:100px\n }\n .bio .card .k{font-family:'IBM Plex Mono',monospace;font-size:11px;letter-spacing:2px;text-transform:uppercase;color:var(--steel-bright);margin-bottom:16px}\n .bio .card .line{font-family:'Newsreader',serif;font-size:19px;line-height:1.4;color:var(--white);margin-bottom:18px}\n .bio .card .sub{font-size:14px;color:rgba(251,250,247,.7);line-height:1.6}\n @media(max-width:760px){.bio .grid{grid-template-columns:1fr;gap:36px}.bio .card{position:static}}\n\n \/* ---- brokerage band ---- *\/\n .band{background:var(--ink);color:var(--paper)}\n .band .wrap{padding:64px 40px;display:grid;grid-template-columns:auto 1fr;gap:48px;align-items:center}\n .band .k{font-family:'IBM Plex Mono',monospace;font-size:11px;letter-spacing:2px;text-transform:uppercase;color:var(--steel-bright);white-space:nowrap}\n .band p{font-family:'Newsreader',serif;font-size:21px;line-height:1.5;color:rgba(251,250,247,.92)}\n .band p b{color:var(--white);font-weight:500}\n @media(max-width:680px){.band .wrap{grid-template-columns:1fr;gap:18px}}\n\n \/* ---- contact ---- *\/\n .contact{padding:100px 0;text-align:center}\n .contact .eyebrow{margin-bottom:22px}\n .contact h2{font-size:36px;line-height:1.22;max-width:20ch;margin:0 auto 22px;color:var(--ink);font-weight:400}\n .contact .sec-p{margin:0 auto 40px;text-align:center}\n .contact .btn{\n display:inline-block;background:var(--steel);color:var(--white);text-decoration:none;\n font-family:'IBM Plex Sans',sans-serif;font-size:15px;font-weight:600;letter-spacing:.3px;\n padding:16px 40px;border-radius:3px;transition:background .2s\n }\n .contact .btn:hover{background:var(--ink)}\n .contact .direct{margin-top:34px;font-family:'IBM Plex Mono',monospace;font-size:13.5px;color:var(--muted);letter-spacing:.5px}\n .contact .direct a{color:var(--ink);text-decoration:none;border-bottom:1px solid var(--brass);padding-bottom:2px}\n .contact .direct a:hover{color:var(--steel)}\n .contact .direct .sep{margin:0 14px;color:var(--line)}\n\n \/* ---- footer ---- *\/\n footer{border-top:1px solid var(--line);background:var(--paper)}\n footer .wrap{padding:40px 40px;display:flex;justify-content:space-between;align-items:center;flex-wrap:wrap;gap:16px}\n footer .brand .mark{font-size:18px}\n footer .tag{font-family:'Newsreader',serif;font-style:italic;font-size:15px;color:var(--steel)}\n footer .fine{width:100%;font-size:12px;color:#a29f96;line-height:1.65;border-top:1px solid var(--line);padding-top:22px;margin-top:8px;font-family:'IBM Plex Sans',sans-serif}\n<\/style>\n<\/head>\n<body>\n\n<div class=\"topbar\">\n <div class=\"wrap\">\n <a href=\"#top\" class=\"brand\">\n <img decoding=\"async\" src=\"https:\/\/sixlogpharma.com\/wp-content\/uploads\/2025\/02\/teal.png\" alt=\"SixLog Pharma\" class=\"logo-img\"> \n \n <\/a>\n <nav>\n <a href=\"#work\">Services<\/a>\n <a href=\"#who\">Who we help<\/a>\n <a href=\"#about\">About<\/a>\n <a href=\"#contact\">Contact<\/a>\n <\/nav>\n <\/div>\n<\/div>\n\n<a id=\"top\"><\/a>\n<header class=\"hero\">\n <div class=\"wrap\">\n <div class=\"eyebrow\">Operational \u00b7 Regulatory \u00b7 Coverage Advisory<\/div>\n <h1>Sterile compounding fails in two places. We work on <em>both.<\/em><\/h1>\n <p class=\"lede\">\n SixLog Pharma helps sterile compounding operations see their full risk picture: how the operation\n runs, where it is exposed, and whether the coverage behind it would respond when something slips\n through. Led by a former 503B owner-operator, we read the operation and the policy from the inside.\n <\/p>\n <\/div>\n<\/header>\n\n<div class=\"spine\">\n <div class=\"wrap\">\n <div class=\"grid\">\n <div class=\"cell\">\n <div class=\"idx\">01 \/ PREVENTION<\/div>\n <h3>Keeping the event from happening<\/h3>\n <p>\n The quality system, environmental monitoring, aseptic technique, CAPA discipline. The work\n that stops the excursion, the failed media fill, the contamination event. Most good operators\n have built this half with real rigor.\n <\/p>\n <\/div>\n <div class=\"cell\">\n <div class=\"idx\">02 \/ SURVIVAL<\/div>\n <h3>Surviving the one that gets through<\/h3>\n <p>\n A recall, a regulatory hold, an officer named personally. Whether the coverage behind the\n business actually responds, or was quietly written for a smaller, simpler version of the\n company. This is the half almost no one checks.\n <\/p>\n <\/div>\n <\/div>\n <div class=\"verdict\">Operations prevent the event. Coverage decides whether the business survives it.<\/div>\n <\/div>\n<\/div>\n\n<section id=\"work\" class=\"svc\">\n <div class=\"wrap\">\n <div class=\"sec-head\">\n <span class=\"eyebrow\">Services<\/span>\n <h2 class=\"sec-h\">Operations and coverage, read from the operator's side.<\/h2>\n <p class=\"sec-p\">\n Most advisors see one half. A quality consultant reads the operation. A broker reads the policy.\n We read both, because they are the same risk, and we read them the way someone does who has run\n the facility and made the call.\n <\/p>\n <\/div>\n <div class=\"rows\">\n <div class=\"row\">\n <div class=\"num\">01<\/div>\n <h3>Operational risk review<\/h3>\n <p>An operator's read of the facility, quality systems, and practices. Where the operation is vulnerable, what an inspection would surface, and what it means for the business, not just the quality file.<\/p>\n <\/div>\n <div class=\"row\">\n <div class=\"num\">02<\/div>\n <h3>Coverage review<\/h3>\n <p>A line-by-line read of the insurance program against what the operation actually does: recall trigger, business interruption from a shutdown, D&O exposure, limits sized to current volume, and the exclusions buried in the endorsements.<\/p>\n <\/div>\n <div class=\"row\">\n <div class=\"num\">03<\/div>\n <h3>Regulatory remediation<\/h3>\n <p>Support through 483 responses, warning letters, and remediation. Building a response that addresses the system, not just the observations, from someone who has been on the receiving end of an inspection.<\/p>\n <\/div>\n <div class=\"row\">\n <div class=\"num\">04<\/div>\n <h3>Transaction diligence<\/h3>\n <p>For buyers, investors, and operators in a deal: an independent read on where a target's operation, compliance, and coverage actually stand, before the exposure becomes yours.<\/p>\n <\/div>\n <\/div>\n <\/div>\n<\/section>\n\n<section id=\"who\" class=\"who\">\n <div class=\"wrap\">\n <div class=\"sec-head\">\n <span class=\"eyebrow\">Who we help<\/span>\n <h2 class=\"sec-h\">The people who own the exposure.<\/h2>\n <\/div>\n <div class=\"list\">\n <div class=\"li\"><span class=\"m\">A<\/span><span class=\"t\"><b>503B outsourcing facilities<\/b> and sterile compounding operations<\/span><\/div>\n <div class=\"li\"><span class=\"m\">B<\/span><span class=\"t\"><b>503A pharmacies<\/b> scaling into new lines or volume<\/span><\/div>\n <div class=\"li\"><span class=\"m\">C<\/span><span class=\"t\"><b>Owners<\/b> preparing for growth, a raise, or a sale<\/span><\/div>\n <div class=\"li\"><span class=\"m\">D<\/span><span class=\"t\"><b>Investors and PE groups<\/b> underwriting a pharmacy acquisition<\/span><\/div>\n <div class=\"li\"><span class=\"m\">E<\/span><span class=\"t\"><b>Consultants<\/b> who advise operators and need the coverage piece<\/span><\/div>\n <div class=\"li\"><span class=\"m\">F<\/span><span class=\"t\"><b>Boards and officers<\/b> exposed personally to regulatory action<\/span><\/div>\n <\/div>\n <\/div>\n<\/section>\n\n<section id=\"about\" class=\"bio\">\n <div class=\"wrap\">\n <div class=\"sec-head\"><span class=\"eyebrow\">About<\/span><\/div>\n <div class=\"grid\">\n <div>\n <h2>Brian Williamson, PharmD<\/h2>\n <div class=\"role\">Founder, SixLog Pharma<\/div>\n <p>\n We built, ran, and sold a nationally recognized sterile compounding pharmacy and FDA-registered\n 503B outsourcing facility. We have lived the environmental excursion, the recall decision, the\n inspection, the choice between stopping a line and pushing through. <b>We know what these\n operations are exposed to, because we ran one.<\/b>\n <\/p>\n <p>\n After building and selling in this industry, we turned to the risks operators live with but rarely have\n time to step back and see whole: the operational exposures, the regulatory ones, and the\n coverage that is supposed to catch what gets through. <b>Seeing that full picture is the work\n now.<\/b>\n <\/p>\n <p>\n We read coverage the way an operator reads a facility: against what the business actually does,\n looking for what others miss. When placement is needed, we work with a specialty life science\n insurance brokerage with real depth in reviewing and structuring policies for high-hazard risk.\n <\/p>\n <p>\n This is not theory from the sidelines. We are actively engaged today, advising sterile\n compounding operators, supporting regulatory remediation, and conducting operational and\n coverage due diligence on live transactions. <b>We do this work now, in the field, not from a\n past life.<\/b>\n <\/p>\n\n <\/div>\n <div class=\"card\">\n <div class=\"k\">Former 503B Owner-Operator<\/div>\n <div class=\"line\">Built it. Ran it. Sold it.<\/div>\n <div class=\"sub\">Now we read the operation and the coverage behind operations like the ones we ran, from the inside.<\/div>\n <\/div>\n <\/div>\n <\/div>\n<\/section>\n\n<div class=\"band\">\n <div class=\"wrap\">\n <div class=\"k\">Placement Partner<\/div>\n <p>\n When coverage needs to be placed or restructured, we work alongside a <b>specialty life science\n insurance brokerage<\/b> with real expertise in reviewing and structuring policies for high-hazard,\n highly regulated operations.\n <\/p>\n <\/div>\n<\/div>\n\n<section id=\"contact\" class=\"contact\">\n <div class=\"wrap narrow\">\n <span class=\"eyebrow\">Start here<\/span>\n <h2>Would your coverage respond to the recall you're most likely to make?<\/h2>\n <p class=\"sec-p\">\n Most operators have never checked. A short conversation is usually enough to know whether it is\n worth a closer look. No pitch, no obligation.\n <\/p>\n <a href=\"mailto:brian@sixlogpharma.com?subject=SixLog%20risk%20and%20coverage%20review\" class=\"btn\">Request a review<\/a>\n <div class=\"direct\">\n <a href=\"mailto:brian@sixlogpharma.com?subject=SixLog%20risk%20and%20coverage%20review\">brian@sixlogpharma.com<\/a>\n <span class=\"sep\">\/<\/span>316.304.5501\n <\/div>\n <\/div>\n<\/section>\n\n<footer>\n <div class=\"wrap\">\n <a href=\"#top\" class=\"brand\"><span class=\"mark\"><b>SixLog<\/b> Pharma<\/span><\/a>\n <div class=\"tag\">Find the gaps before the gaps find you.<\/div>\n <div class=\"fine\">\n SixLog Pharma is a risk advisory practice led by a former 503A and 503B owner-operator. Insurance\n placement is handled in partnership with a licensed specialty insurance brokerage. Content on this\n site is educational and general in nature and is not insurance, legal, or financial advice. Actual\n coverage depends entirely on the specific terms, forms, and endorsements of a given program.\n <\/div>\n <\/div>\n<\/footer>\n\n<\/body>\n<\/html>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>SixLog Pharma \u2014 Operational, Regulatory, and Coverage Advisory for Sterile Compounding Services Who we help About Contact Operational \u00b7 Regulatory \u00b7 Coverage Advisory Sterile compounding fails in two places. We work on both. SixLog Pharma helps sterile compounding operations see their full risk picture: how the operation runs, where it is exposed, and whether the …<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_canvas","meta":{"_genesis_block_theme_hide_title":false,"footnotes":""},"class_list":["post-41","page","type-page","status-publish","hentry","post","without-featured-image"],"_links":{"self":[{"href":"https:\/\/sixlogpharma.com\/index.php?rest_route=\/wp\/v2\/pages\/41","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sixlogpharma.com\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/sixlogpharma.com\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/sixlogpharma.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/sixlogpharma.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41"}],"version-history":[{"count":11,"href":"https:\/\/sixlogpharma.com\/index.php?rest_route=\/wp\/v2\/pages\/41\/revisions"}],"predecessor-version":[{"id":55,"href":"https:\/\/sixlogpharma.com\/index.php?rest_route=\/wp\/v2\/pages\/41\/revisions\/55"}],"wp:attachment":[{"href":"https:\/\/sixlogpharma.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}